| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |